1. Home
  2. RGEN vs JHG Comparison

RGEN vs JHG Comparison

Compare RGEN & JHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
  • JHG
  • Stock Information
  • Founded
  • RGEN 1981
  • JHG 1934
  • Country
  • RGEN United States
  • JHG United Kingdom
  • Employees
  • RGEN N/A
  • JHG N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • JHG Investment Managers
  • Sector
  • RGEN Health Care
  • JHG Finance
  • Exchange
  • RGEN Nasdaq
  • JHG Nasdaq
  • Market Cap
  • RGEN 9.1B
  • JHG 7.3B
  • IPO Year
  • RGEN N/A
  • JHG N/A
  • Fundamental
  • Price
  • RGEN $158.99
  • JHG $41.86
  • Analyst Decision
  • RGEN Buy
  • JHG Hold
  • Analyst Count
  • RGEN 11
  • JHG 11
  • Target Price
  • RGEN $180.63
  • JHG $42.73
  • AVG Volume (30 Days)
  • RGEN 652.6K
  • JHG 1.0M
  • Earning Date
  • RGEN 02-20-2025
  • JHG 01-31-2025
  • Dividend Yield
  • RGEN N/A
  • JHG 3.73%
  • EPS Growth
  • RGEN N/A
  • JHG 8.02
  • EPS
  • RGEN N/A
  • JHG 2.56
  • Revenue
  • RGEN $634,439,000.00
  • JHG $2,473,200,000.00
  • Revenue This Year
  • RGEN $2.28
  • JHG $7.03
  • Revenue Next Year
  • RGEN $9.69
  • JHG $7.86
  • P/E Ratio
  • RGEN N/A
  • JHG $16.35
  • Revenue Growth
  • RGEN 0.33
  • JHG 17.67
  • 52 Week Low
  • RGEN $113.50
  • JHG $30.35
  • 52 Week High
  • RGEN $203.13
  • JHG $46.68
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 53.41
  • JHG 39.69
  • Support Level
  • RGEN $143.83
  • JHG $42.91
  • Resistance Level
  • RGEN $169.00
  • JHG $44.37
  • Average True Range (ATR)
  • RGEN 5.95
  • JHG 1.06
  • MACD
  • RGEN -0.24
  • JHG -0.29
  • Stochastic Oscillator
  • RGEN 61.46
  • JHG 6.41

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About JHG Janus Henderson Group plc

Janus Henderson Group provides investment management services to retail intermediary (56% of managed assets), self-directed (23%) and institutional (21%) clients. At the end of September 2024, active equities (63%), fixed-income (21%), multi-asset (14%) and alternative (2%) investment platforms constituted the company's $382.3 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (61%), with customers from Europe, the Middle East, Africa, and Latin America (29%) and the Asia-Pacific region (10%) accounting for the remainder.

Share on Social Networks: